Top line decelerating.
+16.7% YoY versus +60.6% prior. 3y CAGR +42.2%.
+16.7%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $10.8B
Fundamentals as of 2026-03-31
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
The Question
2 of 2 legendary models say BUY GMED.
What would legendary investors pay for GMED?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
Concerns — Globus Medical, Inc.'s 12.4% ROE is below sector median.
Financial story
Concerns — Globus Medical, Inc.'s 12.4% ROE and 0.15 debt-to-equity warrant a closer look at the underlying business.
Bottom line: GMED is rated BUY by all 2 legendary models, 32% below avg fair value $116, but earns a B sector grade (67/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
2 of 2 legendary investor models rate GMED a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
Average fair value across qualifying models: $116. See the per-investor fair-value table in the valuation tab.
GMED trades at 18.2x earnings. Sector context and per-investor signals are in the valuation tab.
GMED and BMRN differ on P/E, ROE, and revenue growth. See the full GMED vs BMRN compare matrix.
Buffett and Lynch evaluate GMED against their respective frameworks. Per-model fair value and reasoning are in the valuation tab.
GMED's P/E ratio is 18.2x. 5-year P/E history is in the
How does GMED compare?
+16.7% YoY versus +60.6% prior. 3y CAGR +42.2%.
+16.7%Net margin 18.3% versus 4.1% prior (+14.2pp). Operating 16.3%.
18.3%P/E 18.7x — 43% below the 5y median of 32.9x. Forward 16.7x hints at EPS expansion next year.
18.7xSee exactly where GMED ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingGMED sits at #8 in Healthcare with a B grade (67/100).